A New Look at Peptic Ulcer

  1. MORTON I. GROSSMAN, M.D., Ph.D.;
  2. PAUL H. GUTH, M.D.;
  3. JON I. ISENBERG, M.D.;
  4. EDWARD P. PASSARO, Jr., M.D.;
  5. BENNETT E. ROTH, M.D.;
  6. RICHARD A. L. STURDEVANT, M.D.; and
  7. JOHN H. WALSH, M.D.
  1. Los Angeles, California

    Abstract

    There have been notable advances in knowledge about peptic ulcer recently. Gastrin-producing tumors have been recognized as a rare cause of ulcer, and multiple physiologic defects have been found in duodenal ulcer, including excessive release of gastrin after food intake, increased sensitivity to gastrin, and decreased inhibition by low pH. The tendency of gastric ulcer patients to reflux duodenal contents into the stomach may have pathogenetic significance. Two new classes of drugs strongly inhibit acid secretion in man: chemically modified prostaglandins and histamine analogues which block the action of histamine on acid secretion. Their value in treating ulcer is now being assessed in clinical trials. A new operation for duodenal ulcer shows promise: only those vagal fibers innervating the acid-secreting part of the stomach are severed, thus obviating the need for a drainage procedure and decreasing some of the undesirable side effects of earlier operations.

    Article and Author Information

    • ▸An edited transcription of an Interdepartmental Clinical Case Conference arranged by the Department of Medicine of the UCLA School of Medicine, Los Angeles, California.

    • ▸Requests for reprints should be addressed to Morton I. Grossman, M.D., Veterans Administration Wadsworth Hospital Center, Building 115, Room 115, Los Angeles, CA 90073.

      • Received September 25, 1975.
      • Accepted October 15, 1975.
    « Previous | Next Article »Table of Contents